Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating multiple treatment combinations for women with breast cancer that is inoperable, locally advanced, or metastatic. This Phase IbII open-label study includes participants with estrogen receptor-positive ER, HER2-positive or negative breast cancer, some with specific mutations or prior treatment histories. The study allows flexibility to open, close, or modify treatment groups based on ongoing results and patient needs. Participants receive various drugs orally or by subcutaneous injection, including giredestrant alone or combined with other drugs like abemaciclib, ipatasertib, inavolisib, ribociclib, everolimus, samuraciclib, atezolizumab, and a fixed-dose combination of pertuzumab and trastuzumab. Dosage schedules vary, commonly using 28-day or 21-day cycles, continuing until unacceptable side effects or disease progression. Different cohorts focus on distinct breast cancer subtypes and prior treatments, and the study monitors responses over time. During the study, participants undergo evaluations including tumor measurements using RECIST v1.1 criteria, imaging for heart function, and biomarker testing from tumor or blood samples. Researchers assess tumor response, disease control, survival, and adverse events throughout treatment and follow-up up to six years. Safety is closely monitored, and participants may have tumor biopsies if treatment changes occur. The study aims to understand how effective and safe these treatment combinations are for different breast cancer patient groups.
Actively Recruiting
Researchers are evaluating multiple treatment combinations for people with metastatic or inoperable locally advanced breast cancer. This umbrella study includes several patient groups based on cancer type and prior treatments. The goal is to assess the safety and effectiveness of these combinations in different breast cancer subtypes, including triple-negative, hormone receptor-positive, and HER2-positive or HER2-low disease. Participants are assigned to various treatment arms depending on their cohort. Treatments include combinations of drugs such as atezolizumab, nab-paclitaxel, capecitabine, ipatasertib, and trastuzumab deruxtecan, among others. Some participants may continue to a second treatment stage if their cancer progresses or if side effects occur, provided they meet specific criteria. During the study, participants will have regular assessments including tumor measurements, biopsies for biomarker analysis, and lab tests to monitor health and treatment effects. Researchers will measure outcomes like the tumor response rate, progression-free survival, overall survival, and side effects over up to 12 years. Participants are monitored closely to track safety and treatment impact throughout the study.